Faculty Opinions recommendation of CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

2009 ◽  
Author(s):  
Brian Huntly ◽  
Brynn Kvinlaug
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Prognostic Factor ◽  
Myeloid Leukemia ◽  
Therapeutic Antibody ◽  
Leukemia Stem Cells ◽  
Adverse Prognostic Factor ◽  
Human Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Cell ◽  
2009 ◽  
Vol 138 (2) ◽  
pp. 286-299 ◽  
Author(s):  
Ravindra Majeti ◽  
Mark P. Chao ◽  
Ash A. Alizadeh ◽  
Wendy W. Pang ◽  
Siddhartha Jaiswal ◽  
...  
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Prognostic Factor ◽  
Myeloid Leukemia ◽  
Therapeutic Antibody ◽  
Leukemia Stem Cells ◽  
Adverse Prognostic Factor ◽  
Human Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Biology and relevance of human acute myeloid leukemia stem cells

Blood ◽  
2017 ◽  
Vol 129 (12) ◽  
pp. 1577-1585 ◽  
Author(s):  
Daniel Thomas ◽  
Ravindra Majeti
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Cell Model ◽  
Experimental Manipulation ◽  
Biological Properties ◽  
Leukemia Stem Cells ◽  
Future Research ◽  
Human Acute Myeloid Leukemia ◽  
Acute Myeloid

Abstract Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly 2 decades ago through the identification of rare subpopulations of engrafting cells in xenotransplantation assays. These AML LSCs were shown to reside at the apex of a cellular hierarchy that initiates and maintains the disease, exhibiting properties of self-renewal, cell cycle quiescence, and chemoresistance. This cancer stem cell model offers an explanation for chemotherapy resistance and disease relapse and implies that approaches to treatment must eradicate LSCs for cure. More recently, a number of studies have both refined and expanded our understanding of LSCs and intrapatient heterogeneity in AML using improved xenotransplant models, genome-scale analyses, and experimental manipulation of primary patient cells. Here, we review these studies with a focus on the immunophenotype, biological properties, epigenetics, genetics, and clinical associations of human AML LSCs and discuss critical questions that need to be addressed in future research.

scholarly journals IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis

Cell Reports ◽  
2018 ◽  
Vol 25 (11) ◽  
pp. 3021-3035.e5 ◽  
Author(s):  
Han J.M.P. Verhagen ◽  
Noortje van Gils ◽  
Tania Martiañez ◽  
Anna van Rhenen ◽  
Arjo Rutten ◽  
...  
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Leukemia Stem Cells ◽  
Human Acute Myeloid Leukemia ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document